Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070831 | 0.85 | IP6K1 (0.44) | NMT1MAPTSMN1; SMN2TP53NMT2 | |
| SCHEMBL1486598 | 0.84 | NMT1 (0.49) | NMT1MAPTSMN1; SMN2TP53NMT2 | |
| SCHEMBL1486634 | 0.84 | NMT1 (0.41) | NMT1MAPTSMN1; SMN2TP53NMT2 | |
| SCHEMBL3869604 | 0.83 | NMT1 (0.49) | NMT1MAPTSMN1; SMN2TP53NMT2 | |
| SCHEMBL6411140 | 0.81 | HRH3 (0.46) | SMN1; SMN2LMNA | |
| SCHEMBL1486569 | 0.80 | NMT1 (0.50) | NMT1MAPTNMT2EGFRERBB2 | |
| SCHEMBL1486522 | 0.79 | NMT1 (0.46) | NMT1MAPTSMN1; SMN2NMT2EGFR | |
| SCHEMBL1486511 | 0.79 | NMT1 (0.44) | NMT1MAPTSMN1; SMN2TP53NMT2 | |
| SCHEMBL1486487 | 0.78 | NMT1 (0.47) | NMT1MAPTSMN1; SMN2NMT2EGFR | |
| SCHEMBL4067389 | 0.76 | CYP3A4 (0.40) | NMT1MAPTSMN1; SMN2EGFRIP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658076-B1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8263594-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-7897597-B2 | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018122-A1 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines | IL2, IFNG, IRF3 | NMT1 3893/4885MAPT 4765/4885SMN1; SMN2 4043/4885 |
| US-20110144099-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | NMT1 3677/4885MAPT 4760/4885SMN1; SMN2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.